Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,160 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (561)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03572582 | Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma(IMMUTACE) | completed | Phase 2 | 49 | AIO-Studien-gGmbHOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT04975932 | Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study(CHANCE001) | completed | — | 826 | Zhongda HospitalOTHER | 1 | Jul 14, 2023 |
| clinicaltrials |
| NCT00699816 | Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients | completed | Phase 3 | 230 | GC Cell CorporationINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT02424955 | Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation | completed | N/A | 11 | Stanford UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04823754 | Perception of the Doctor/Patient Relationship, Disease and Treatment Among Physicians and Their Patients Treated With Systemic Therapy for Hepatocellular Carcinoma "PERCEPTION1"(PERCEPTION1) | completed | — | 150 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03222076 | Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT00003907 | Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver | completed | Phase 2 | 50 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02795429 | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | completed | Phase 1 / Phase 2 | 89 | Novartis PharmaceuticalsINDUSTRY | 8 | Jul 3, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05116891 | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Cantargia ABINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT03278106 | TAS-102 in Treating Advanced Biliary Tract Cancers | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01890291 | Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.(Immuncell-LC) | completed | — | 162 | GC Cell CorporationINDUSTRY | 1 | Jun 26, 2023 | clinicaltrials |
| NCT01897610 | Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC | completed | Phase 2 | 40 | GC Cell CorporationINDUSTRY | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04217954 | HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC | completed | Phase 2 | 32 | Peking UniversityOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT02856815 | Safety and Efficacy of "Immuncell-LC" in TACE Therapy | completed | Phase 2 | 76 | GC Cell CorporationINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02513199 | Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 32 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05907772 | Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma | completed | — | 522 | Zhejiang UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02520141 | Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery | completed | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03473574 | Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients(IMMUCHEC) | completed | Phase 2 | 128 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05304572 | Multi-Detector CT Angiography With 3D Reconstruction Versus Digital Subtraction Angiography | completed | — | 70 | Assiut UniversityOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00813293 | Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer | completed | Phase 2 | 20 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT05213221 | Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients(CISLD-12) | completed | Phase 2 | 39 | Zhejiang UniversityOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02973685 | HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B. | completed | Phase 3 | 315 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT04044313 | HAIC Plus Lenvatinib and Toripalimab for Advanced HCC | completed | Phase 2 | 36 | Shi MingOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05030090 | Integrative Nutrition Care Plan for the Patient With Liver and Colorectal Cancer | completed | N/A | 66 | Taipei Medical UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT01658917 | Collecting Solid Tumor Tissue to Identify New Treatments | completed | — | 133 | National Cancer Institute (NCI)NIH | 1 | May 30, 2023 | clinicaltrials |
| NCT04837742 | The Effect of Ultrasound-guided Erector Spinae Plane Block on Postoperative Analgesia in Radiofrequency Ablation Therapy | completed | N/A | 30 | National Taiwan University HospitalOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT02351765 | ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers(ABC-08) | completed | Phase 1 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT04681274 | Phenotyping Liver Cancer Registry(PHELICAR) | completed | — | 2,429 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT03841201 | Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | completed | Phase 2 | 50 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT04641637 | Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCC | completed | N/A | 40 | Chinese University of Hong KongOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy(EPIC-1511) | completed | Phase 3 | 480 | Centre Oscar LambretOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT03586973 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 34 | TakedaINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04970212 | Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures | completed | — | 65 | Techsomed Medical Technologies LTDINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT01943318 | Boramae Hospital Liver Cirrhosis Patient Cohort Study | completed | — | 500 | Seoul National University Boramae HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05804799 | Liver CT Dose Reduction With Deep Learning Based Reconstruction | completed | — | 300 | Seoul National University HospitalOTHER | 2 | Apr 12, 2023 | clinicaltrials |
| NCT04653818 | HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial(RCT) | completed | Phase 4 | 84 | Alexandria UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03895970 | Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors | completed | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT02821754 | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05772403 | Contrast Enhanced Ultrasound (CEUS) in Atypical Liver Nodules in Patients With Chronic Liver Disease | completed | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT03801915 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT04124991 | Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC(SOLID) | completed | Phase 1 / Phase 2 | 24 | Seoul National University HospitalOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT01192971 | A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma(HCC) | completed | Phase 2 | 121 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05739110 | HCC Staging Modified by Tumor Micronecrosis | completed | — | 1,100 | Zhejiang UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02683200 | MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer | completed | Early Phase 1 | 21 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05028439 | RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma | completed | N/A | 70 | First People's Hospital of HangzhouOTHER | 1 | Feb 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 20, 2023source: clinicaltrials